1. Academic Validation
  2. Toll-like receptor 4 antagonist TAK-242 inhibits autoinflammatory symptoms in DITRA

Toll-like receptor 4 antagonist TAK-242 inhibits autoinflammatory symptoms in DITRA

  • J Autoimmun. 2017 Jun;80:28-38. doi: 10.1016/j.jaut.2017.01.007.
Akitaka Shibata 1 Kazumitsu Sugiura 2 Yasuhide Furuta 3 Yoshiko Mukumoto 4 Osamu Kaminuma 5 Masashi Akiyama 6
Affiliations

Affiliations

  • 1 Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Dermatology, Gifu Prefectural Tajimi Hospital, Tajimi, Japan.
  • 2 Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
  • 3 Animal Resource Development Unit, RIKEN Center for Life Science Technologies, Kobe, Japan.
  • 4 Animal Resource Development Unit, RIKEN Center for Life Science Technologies, Kobe, Japan; Genetic Engineering Team, RIKEN Center for Life Science Technologies, Kobe, Japan.
  • 5 Department of Genome Medicine, Allergy and Immunology Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan; The Center for Life Science Research, University of Yamanashi, Chuo, Japan.
  • 6 Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: makiyama@med.nagoya-u.ac.jp.
Abstract

Background: IL36RN encodes the IL-36 receptor antagonist (IL-36RA), and loss-of-function mutations in IL36RN define a recessively inherited autoinflammatory disease named "deficiency of IL-36Ra" (DITRA). DITRA causes systemic autoinflammatory diseases, including generalized pustular psoriasis (GPP), an occasionally life-threatening disease that is characterized by widespread sterile pustules on the skin, fever and other systemic symptoms. GPP can present at any age, and provocative factors include various infections, medicines and pregnancy.

Objective: We aimed to elucidate the role of Toll-like Receptor 4 (TLR4) signaling in DITRA and to innovate an efficient treatment for DITRA.

Methods: We generated Il36rn-/- mice and treated them with TLR4 Agonist to establish DITRA model mice. Furthermore, we administrated TLR4 Antagonist TAK-242 to the model mice to inhibit the DITRA symptoms.

Result: Il36rn-/- mice treated by TLR4 Agonist showed autoinflammatory symptoms in skin, articulation and liver. Thus, we established model mice for DITRA or GPP that show cutaneous, articular, and hepatic autoinflammatory symptoms typical of DITRA or GPP: sterile pustules on the skin, liver abscesses and enthesitis of the hind paws. Additionally, these symptoms were canceled by TAK-242 administration. We demonstrated the inhibitory effects of the TLR4 Antagonist TAK-242 on the autoinflammatory symptoms exhibited by the DITRA models.

Conclusion: We suggested that blockage of TLR4 signaling is a promising treatment for DITRA and GPP.

Keywords

Autoinflammation; Deficiency of IL-36 receptor antagonist; Generalized pustular psoriasis; LPS; TAK-242; Toll-like receptor 4.

Figures
Products